Intercept Pharmaceuticals, Inc. Logo
 
Press Releases
Date Title and Summary View
Jul 6, 2016 NEW YORK, July 06, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today the closing of its previously announced underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes), including the full exercise by the underwriters of an option to pur...
Jun 30, 2016 NEW YORK, June 30, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today the pricing of its previously announced underwritten public offering of $400 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes). Intercept has granted the underwriters an option, exercisable for 30 ...
Jun 29, 2016 NEW YORK, June 29, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today that it has commenced an underwritten public offering of $400 million aggregate principal amount of convertible senior notes due 2023 (the notes). RBC Capital Markets, UBS Investment Bank, BofA Merrill Lynch, Citigroup and Credit Suisse ...
Jun 9, 2016 NEW YORK, June 09, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced  the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succ...
Jun 1, 2016 NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences: ...
May 27, 2016 First new medicine for PBC in nearly 20 years Investor conference call Tuesday, May 31 at 8:30 a.m. ET NEW YORK, May 27, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and ...
May 18, 2016 NEW YORK, May 18, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that five abstracts evaluating obeticholic acid (OCA) in patients with prim...
May 5, 2016 NEW YORK, May 05, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today reported financial results for the quarter ended March 3...
Apr 28, 2016 NEW YORK, April 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report first quarter 2016 financial results after the NASDAQ ...
Apr 16, 2016 NEW YORK, April 16, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the winners of its Practice to Policy Health Awards Prog...
Page:
1
... NextLast
= add release to Briefcase